BLAINJECTIONINJECTABLE
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
YESINTEK (ustekinumab) by Biocon is interleukin-12 antagonists [moa]. Approved for psoriasis, crohn's disease, ulcerative colitis and 2 more indications. First approved in 2024.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YESINTEK (ustekinumab) is a monoclonal antibody that blocks interleukin-12, an immune signaling molecule driving inflammatory disease. It treats psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and inflammatory bowel disease by dampening the Th1/Th17 immune response. This IL-12 antagonist represents a distinct mechanistic approach within the immunosuppressive landscape.
Growth
Early-stage growth product with modest baseline ASP suggests a scaling commercial organization building infrastructure for competitive indication expansion.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications (5)
Worked on YESINTEK at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.